Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Morgan Stanley Boosts Nvidia and Broadcom Targets as AI Demand Surges 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Bristol Myers Faces $6.7 Billion Lawsuit After Judge Allows Key Shareholder Claims to Proceed 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Pharmaceutical giants are pivoting toward direct-to-consumer sales and offering steep drug discounts in the United States after President Donald Trump called for lower prescription prices and reduced reliance on “middlemen” such as insurers and pharmacy benefit managers. The move comes ahead of the Trump administration’s planned TrumpRx.gov launch in early 2026 — a federal website that will feature reduced drug prices.
U.S. patients currently pay nearly three times more for medicines than those in other developed countries. Following Trump’s July letters to 17 major firms demanding price cuts, several have responded with new pricing and sales models.
AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at the same U.S. price, aligning with Trump’s “most-favored-nation” pricing policy. AstraZeneca struck a deal with the administration to sell select drugs at steep discounts through Medicaid and TrumpRx.gov, with up to 80% price reductions on some medicines. Bristol-Myers Squibb will cut prices on its blood clot drug Eliquis and plaque psoriasis treatment Sotyktu.
Eli Lilly began shipping high-dose Zepbound directly to consumers, while Novo Nordisk partnered with telehealth providers like GoodRx, Hims & Hers, and Ro to offer Ozempic and Wegovy to cash-paying patients. Pfizer also agreed to lower Medicaid prices to match global rates and will invest $70 billion in U.S. R&D in return for tariff relief.
Sanofi introduced a $35 monthly insulin cap for all U.S. patients, and Roche is exploring direct sales to consumers. Women’s telehealth platform Wisp expanded to offer weight-loss drugs from Eli Lilly and Novo Nordisk with home delivery. Zealand Pharma is also weighing a similar model for its experimental obesity treatment.
Industry group PhRMA plans to launch AmericasMedicines.com in January, helping patients buy directly from manufacturers — signaling a major shift toward affordability and accessibility in the U.S. drug market.
